内皮细胞Cpt1a通过抑制内皮细胞-介质细胞过渡来抑制新生儿高氧引起的肺血管重塑,从而抑制新生儿高氧诱导的肺血管重塑
Xiaoyun Li1,2,3,4, Katy Hegarty1, Fanjie Lin5
1Department of Molecular Biology, Cellular Biology, and Biochemistry, Brown University, Providence, RI, 02912, USA.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 12, 2025
概括
新生儿高氧导致婴儿肺高血压 (PH) 通过减少内皮卡尼丁棕转移酶1a (Cpt1a) 和增加内皮-介质细胞过渡 (EndoMT). 向Cpt1a或EndoMT可以治疗与BPD相关的PH.
科学领域:
- 新生儿生理学 新生儿生理学
- 肺血管疾病是肺血管疾病.
- 细胞代谢的细胞代谢.
背景情况:
- 在早产婴儿中,支气管肺功能障碍 (BPD) 与肺高血压 (PH) 的死亡率增加有关.
- 目前对与BPD相关的PH的治疗方法有限,这凸显了对新型治疗策略的需求.
- 内皮卡尼丁棕转移酶1a (Cpt1a) 在细胞代谢中起着至关重要的作用,但其在新生儿PH和BPD中的功能尚不清楚.
研究的目的:
- 在新生儿高氧模型中研究内皮Cpt1a在PH和肺血管重塑的发展中的作用.
- 为了确定Cpt1a的降低是否有助于内皮-介质酶过渡 (EndoMT) 在高氧化引起的肺损伤的背景下.
- 通过调节Cpt1a水平或抑制EndoMT来探索BPD相关PH的潜在治疗点.
主要方法:
- 使用内皮细胞特异性Cpt1a淘汰 (KO) 和野生型 (WT) 鼠标,从12小时起暴露在高氧 (70% O2) 中,持续14天,然后在诺莫克西亚中恢复.
- 使用生理测量和组织学分析评估肺高血压 (PH) 和肺血管 (PV) 重塑.
- 通过免疫光,单细胞RNA测序 (scRNA-seq) 和EC谱系追踪,研究了内皮-介质细胞过渡 (EndoMT).
主要成果:
- 过氧诱导PH,在EC特定的Cpt1aKO小鼠中与WT对照相比,PH恶化.
- 上调的内皮Cpt1a表达减弱过氧诱导的PV重塑.
- 过氧促进了肺EndoMT,而这种过程在EC特定的Cpt1a KO小鼠中进一步增强;阻断EndoMT改善了PV重塑.
- 雄性小鼠表现出比雌性更严重的PH,与内皮Cpt1a表达减少相关.
结论:
- 新生儿高氧症通过降低内皮细胞Cpt1a表达和促进EndoMT而导致PH和PV重塑.
- 内皮Cpt1a缺陷加剧了高氧诱导的PH和PV重塑.
- 针对内皮细胞Cpt1a上调或EndoMT抑制,为BPD相关PH提供了一个有前途的治疗策略.
更多相关视频
08:38Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
1.1K
07:49Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
11.2K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
132
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
132
